Loading...
•
Dec 31, 2024
Biogen Q4 2024 Earnings Report
Key Takeaways
Biogen reported Q4 2024 revenue of $2.46 billion, a 3% increase year-over-year. GAAP diluted EPS was $1.83, up 7% YoY, while Non-GAAP diluted EPS reached $3.44, up 17% YoY. Growth was primarily driven by rare disease revenue and biosimilars, which offset declines in multiple sclerosis products.
Biogen
Biogen
Biogen Revenue by Segment
Biogen Revenue by Geographic Location
Revenue by Segment
Multiple Sclerosis Revenue
CapyFin.comRare Disease Revenue
CapyFin.comBiosimilars Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
Biogen expects FY 2025 revenue to decline by a mid-single digit percentage, driven by further declines in multiple sclerosis product revenue, partially offset by growth in product launches.
Positive Outlook
- Continued revenue growth from LEQEMBI and SKYCLARYS.
- FDA approval for LEQEMBI intravenous maintenance dosing.
- Cost reductions through the Fit for Growth program.
- Pipeline expansion with key late-stage assets.
- Stable operating margin expected for 2025.
Challenges Ahead
- Declining multiple sclerosis product revenue.
- Foreign exchange headwinds impacting financials.
- Increased competition in rare disease treatments.
- Uncertainty around Alzheimer’s collaboration revenue.
- Potential impact of macroeconomic conditions on revenue.
Revenue & Expenses
Visualization of income flow from segment revenue to net income